To assess the cost-effectiveness of a new urinary biomarkerbased risk score (SelectMDx; MDxHealth, Inc., Irvine, CA, USA) to identify patients for transrectal ultrasonography (TRUS)-guided biopsy and to compare this with the current standard of care (SOC), using only prostate-specific antigen (PSA) to select for TRUS-guided biopsy.
Introduction
The standard of care (SOC) in prostate cancer diagnostics relies mainly on serum PSA testing and DRE. Subsequently, a systematic 10-12 core TRUS-guided biopsy is the 'gold standard' to obtain prostate pathology for a definite diagnosis. The problem with this approach is, unfortunately, the low specificity of PSA for (high-grade) prostate cancer, leading to a considerable number of unnecessary biopsies. These men are therefore unnecessarily exposed to potential complications of this procedure, such as infections, LUTS and haematuria [1] . Moreover, this drawback of PSA testing facilitates the diagnosis of clinically insignificant tumours, which in turn can lead to potential overtreatment [2, 3] . Besides the fact that these men are unnecessarily exposed to the potential sideeffects of invasive treatment, being diagnosed with cancer brings a psychological burden to the patient [4] . Finally, over diagnosis and overtreatment also have broader implications, resulting in an increase in healthcare costs for the community [5] . PSA screening studies demonstrated a reduction in prostate cancer mortality attributable to PSA testing; however, the benefit of this screening was diminished by loss of quality-adjusted life years (QALYs) owing to long-term effects after diagnosis [4, 6] .
Proper patient selection for prostate biopsy with a focus on significant disease might improve the diagnostic pathway, reduce the number of unnecessary biopsies, and decrease overtreatment. A recently published new urinary molecular biomarker-based risk score (SelectMDx; MDxHealth, Inc., Irvine, CA, USA) was developed to identify patients that are at risk of harbouring high-grade prostate cancer (Gleason score ≥7) [7] . This risk score is based on the urinary homeobox C6 (HOXC6) and distal-less homeobox 1 (DLX1) mRNA signature in combination with serum PSA level, PSA density, and other clinical risk factors such as age, prior cancer-negative biopsies, DRE, and family history. The multimodal approach, including both traditional and molecular risk factors, reached an area under the curve of 0.86 (95% CI 0.80-0.92) for the prediction of high-grade prostate cancer upon biopsy. In addition, an evaluation of clinical utility using decision curve analysis indicated a strong net benefit to detect high-grade disease and a significant reduction in the number of unnecessary biopsies [7] .
Although this new risk score will be subject to additional clinical validation in further prospective trials, costeffectiveness and quality-of-life (QoL) effects based on the diagnostic performance and clinical consequences should also be addressed in the current light of growing healthcare costs. Therefore, the objective of the present study was to evaluate costs, QoL, and survival effects when using the SelectMDx risk score as a reflex test in men with a PSA level of >3 ng/ mL and comparing this to the SOC in the diagnostic pathway for prostate cancer.
Materials and Methods

Model Development
A decision analytical model was constructed that displays a mathematical method to weigh risks, benefits and costs of clinical strategies (TreeAgePro 2014). A decision tree represented two diagnostic and prostate cancer treatment pathways (Fig. 1) . Subsequently, a decision-analytical Markov model representing the patient follow-up was developed. Each cycle in the model was set to 1 year, meaning that the patients in the cohort had a probability to move to a different health state after each year. One-way sensitivity analyses were performed on the input parameters of the model. After the health event radical prostatectomy (RP) or radiation therapy (RT), patients moved to long-term complications (i.e. postradiotherapy complications, erectile dysfunction, and incontinence). The state after long-term complications or watchful waiting (WW) was death. The combined model was used to evaluate costs, QoL, and survival effects of two different strategies.
The first strategy consisted of the current SOC in which patients with an elevated PSA level (>3 ng/mL) undergo a systematic TRUS-guided biopsy. In case of negative biopsies, follow-up will be performed by the GP. When a patient is diagnosed with a high-grade tumour (Gleason score ≥7) the patient will undergo RP, RT or WW, while active surveillance (AS) will be the main option if a low-grade prostate cancer is detected (Gleason score ≤6). However, for the latter group of patients, curative treatment (RP or RT) can be an alternative.
In the second, experimental strategy, patients with an elevated PSA level (>3 ng/mL) are subsequently evaluated with a SelectMDx test. In case the SelectMDx test is positive, the patient will undergo a systematic TRUS-guided biopsy. When a high-grade or low-grade tumour is detected the same treatment options from the first strategy can be followed. If no tumour is found on biopsy or if the SelectMDx test is negative, the patient will be followed up by the GP. In both strategies it was assumed that patients with a false-negative biopsy or false-negative SelectMDx test would eventually be detected during the continued follow-up. In the model it was assumed that these patients will be detected based on clinical symptoms and therefore are beyond localised disease and will not qualify to undergo curative treatment.
Transition Probabilities
Within the constructed model the cohort of patients moves through different health states according to a set of transition probabilities. The probability of correctly dividing patients with expected high-grade cancer from patients without cancer or low-grade cancer was based on the accuracy of a subset of patients from the SelectMDx validation study (n = 619) who met all clinical input parameters (PSA level, PSA density, age, family history, prior biopsy and DRE) [7] . For the base-case analysis a cut-off point in the SelectMDx risk score was used to divide patients with expected high-grade cancer from patients without cancer or low-grade cancer. This cut-off point resulted in a sensitivity for high-grade prostate cancer of 95.7% and a specificity for low-grade prostate cancer and no prostate cancer of 33.6% and 60.8%, respectively.
Remaining input data for the model were derived from clinical studies and expert opinion as shown in Table 1 [7] [8] [9] . Prostate cancer-specific survival was assumed similar for both RP and RT in the case of high-grade prostate cancer [10] . General survival data were based on the annual survival of the Dutch population from the age of 65 years [11] (online data).
Effectiveness
Effectiveness was measured in terms of QALYs. To arrive at QALYs, health-related QoL was expressed as a utility value 660 © 2017 The Authors BJU International © 2017 BJU International on a scale from 0 (death) to 1 (perfect health), and the life years lived with this utility. The utility scores used for calculation of the QALYs are displayed in Table 2 [4] . For the first year the utility scores were based on the performed biopsy, the diagnosis of prostate cancer, and the applied treatment. After the first year, utility scores were attached to the health events 'no problems', 'long-term complications,' 'AS' or 'death'. The disutility for AS and long-term complications were assumed to be for lifetime. For the latter, the disutility estimate was calculated as a mean disutility for both patients with and without long-term complications.
Cost Information
Costs for biopsy, treatment, long-term complications and AS were incorporated using a healthcare perspective (Table 3) . These costs were based on cost calculations from the Radboud University Medical Center (Radboudumc, Nijmegen, the Netherlands) in the year 2015. To complete the total prostate biopsy costs, mean complication costs were integrated in total biopsy costs. Furthermore, early and late complications of RP and RT were also included (i.e. incontinence, gastro-intestinal toxicity). To reflect the effects and costs over the time horizon of the analysis, QALYs and costs were respectively discounted by 1.5% and 4% according to Dutch guidelines [12] (online data).
Data Analysis
The course of patients in both strategies were simulated over a time horizon representing 18 years, based on the median follow-up time of survival data for patients with prostate cancer, described in a series by Bill-Axelson et al. [8] . Patients entered the model at a median age of 65 years. The impact of different consequences using SelectMDx was analysed. Effects were expressed in terms of missed highgrade tumours, prevented biopsies, prevented treatment of low-grade cancers, and the related differences in costs and QALYs. The effects were determined both per patient and for the population, accounting for the 17 177 patients annually at risk for localised prostate cancer (stage T1/T2) in the Netherlands [13,14] (online data). Analysis was done for two scenarios. In the base-case scenario it was assumed that missing a low-grade tumour had no detrimental effect on survival, while in the alternative scenario finding a low-grade tumour resulted in an absolute risk reduction of dying from prostate cancer of 3.8% due to treatment [8, 15, 16] . Subgroup analysis was performed for men with PSA levels in a grey zone (3-10 ng/mL), as PSA is less directive for clinical outcome in this particular group. Moreover, the disutility estimates of biopsy and AS (Table 2) were assessed in sensitivity analyses. These estimates were evaluated with the given disutility and without disutility.
Results
Cost-Effectiveness of SelectMDx Compared with SOC
In the SOC strategy a patient considered at risk for prostate cancer (PSA level >3 ng/mL) had a probability of 77% of undergoing an unnecessary TRUS-guided biopsy (no prostate cancer or low-grade prostate cancer), while in the SelectMDx strategy this was 36%. Therefore, 41% of these unnecessary biopsies could be prevented. The probability of finding a lowgrade prostate cancer was reduced by 7% (Table 4 ). In comparison with the SOC strategy, using the SelectMDx test, patients had a 1% probability that a high-grade prostate cancer was missed.
In the base case the SelectMDx strategy lowered the costs by €128 per patient relative to the SOC strategy (€2983 vs PCa, prostate cancer; HG, high-grade; LG, low-grade; base case, missing a LG-PCa has no detrimental effect on survival; scenario case, missing a LG-PCa will affect survival in a deleterious manner. *The disutility estimate was calculated as a mean disutility for both patients with and without long-term complications. (Table 4 ). This resulted in a net cost reduction of €2.2 million and an overall gain of 429 QALYs per annual cohort. In the alternative scenario, assuming that finding a low-grade prostate cancer will result in survival benefit, 0.01 QALYs were gained and €129 saved per patient, in favour of the SelectMDx test. This resulted in a total number of 167 QALYs gained with similar overall cost savings as in the base case.
Cost-Effectiveness in the PSA Grey Zone (3-10 ng/mL)
Subgroup analysis of patients with PSA levels between 3 and 10 ng/mL showed a benefit for the SelectMDx test in the base case, with a QALY gain of 0.0326 and a cost reduction of €170 per patient (Table 4 ). In the alternative scenario this was 0.0161 and €171 per patient, respectively.
Impact of the Different Consequences Using SelectMDx
Missing high-grade prostate cancer resulted in a loss of 0.011 QALYs relative to the SOC strategy. The prevention of biopsies due to the SelectMDx test saved €198 and gained 0.0015 QALYs; however, this did not outweigh the extra costs of using SelectMDx and the loss of QALYs due to missed high-grade tumours. The prevention of revealing low-grade tumours (and the subsequent treatment or followup with AS) had the highest impact on the outcome with €199 in saved costs and a net gain of 0.0345 QALYs. This made the SelectMDx a favourable strategy compared with SOC.
Sensitivity Analysis
The disutility assigned to AS patients showed the highest impact on the QALYs. When AS was assumed not to influence the QoL, i.e. no disutility, the SelectMDx test gained 0.0025 QALYs per patient in the base case. However, in the alternative scenario, the SOC strategy was more effective with 0.013 QALYs per patient gained when AS did not influence the QoL. In the alternative scenario analysis, a disutility of at least 0.017 for AS will make the SelectMDx test more costeffective compared to SOC. Treatment of low-grade prostate cancer with RP or RT influenced both QALYs and costs. When all low-grade tumours were followed by AS, instead of treated with RP or RT, the health gain with the SelectMDx test in the base case decreased to 0.0184, with a cost reduction of €7.51 per patient.
When the postoperative recovery duration was set at 9 years instead of lifetime, this changed the net QALY gain per patient to 0.022 in favour of the SelectMDx strategy, relative to SOC. When also the AS duration was changed to 7 years instead of lifetime, this changed the QALY gain per patient to 0.016, still in favour of the SelectMDx strategy.
The disutility attributed to TRUS-guided biopsy did only slightly influence the outcomes of the model. When no disutility for TRUS-guided biopsy was assigned, the difference in QALYs between the strategies was 0.024, which was only slightly lower than in the base-case analyses.
Discussion
The current diagnostic strategy for prostate cancer, based on PSA testing, is associated with a high number of unnecessary prostate biopsies and the detection of clinically insignificant tumours [5] . The present study demonstrated the potential cost-effectiveness of using SelectMDx as a second step diagnostic decision tool to opt for prostate biopsies in a group of patients potentially at risk of prostate cancer. A net 41% of the biopsies could be saved compared to the SOC strategy, with a chosen cut-off for the test corresponding with a negative predictive value of 98% for high-grade prostate cancer. The subsequent prevention of finding low-grade tumours, and the following treatment or AS, was a significant factor in the model. The major part contributing to the QALYs was determined by a loss of QoL in patients on AS, while reduction in radical treatment of low-grade tumours contributed in a lesser extent. The disutility attributed to AS was obtained from two studies from Heijnsdijk et al. [4, 17] . However, they based their assumption on theories described in previous studies, making the actual value to some extent uncertain. Sensitivity analysis showed a health benefit using the SelectMDx test in case the disutility was set at least at 0.017 for AS patients. Both TRUS-guided biopsy and SelectMDx test costs had an important influence on cost outcome, where reducing the SelectMDx test costs can be counted as a direct reduction in cost per patient. QALYs and cost gain slightly decreased in the SelectMDx strategy when all men with low-grade tumours were assigned to AS (instead of 80%), which would be a preferable clinical situation.
Since the validation study of the urinary molecular biomarker-based risk score used in the present study was only recently published, this is the first study to compare this test with SOC from a healthcare perspective [7] . However, recently several papers on the cost-effectiveness of methods to reduce prostate cancer over diagnosis have been published [9, 18, 19] . De Rooij et al. [9] suggested that MRI and MRguided targeted biopsy is cost-effective compared to the SOC using TRUS-guided biopsy, based on the reduction of over diagnosis and overtreatment, while costs were almost equal between both strategies. Heijnsdijk et al. [18] and Nichol et al. [19] assessed the cost-effectiveness of the Prostate Health Index (PHI) for prostate cancer detection and concluded that the use of PSA plus the PHI might reduce the number of negative biopsies and improve the costeffectiveness of prostate cancer detection. In future research it would be interesting to investigate the currently available prostate cancer diagnostic and prognostic methods in a large prospective direct comparison with respect to diagnostic accuracy and cost-effectiveness outcomes.
Although the present results seem promising, the present study is subject to certain limitations that should be considered. The fact that TRUS-guided biopsy is used as the 'gold standard' for prostate cancer diagnosis might underestimate the actual number of patients with (highgrade) prostate cancer [20, 21] . Through the parallel comparison of both strategies in our present study this would not affect the results directly, although it remains an ongoing limitation in prostate cancer biomarker studies. The adverse pathology of low-grade tumours detected by TRUS-guided biopsy, however, could potentially result in a lower sensitivity for the SelectMDx test and affect the results [22] . Nonetheless, in the scenario analysis we assumed that there was a survival difference between revealed and unrevealed tumours, which means that if missed tumours were in fact high-grade tumours, this was accounted for in the model. This scenario analysis resulted in favour of the SelectMDx test; however, the net gain in QALYs was lower compared to the base-case scenario.
As the model was built on assumptions based on data from the literature and accuracy data were based on the validation study of the urinary biomarker-based risk score [7] , outcome may not be irrespectively extrapolated to another population. Moreover, costs were based on Dutch healthcare standards and might therefore not be directly applicable in other countries. Yet, given the presentation of the used model input parameters in our present study, these could be modified for a preferred situation, taking into account the clinical patient features and test accuracy of the modelled population. Also, different discount rates can be considered to reflect the effects and costs over the time horizon of the analysis. In our present analysis, applying no discount or a 5% discount for both QALYs and costs did not have a significant influence on outcome.
Considering no survival data were available for patients not eligible for curative treatment (primary locally advanced or metastatic disease), a conservative approach was chosen and cost-effectiveness was not separately modelled for this group. Assuming 4.3% of patients with high-grade prostate cancer are missed by the SelectMDx strategy, of which~13% will not be eligible for curative treatment, the difference between both diagnostic strategies is only modest [23] . Considering that costs of androgen-deprivation therapy will be lower than costs modelled for RP or RT, this would be in favour of the SelectMDx strategy.
Through this decision analytical model we attempted to reflect the cost-effectiveness of the novel urinary biomarker-based risk score in the current climate of growing healthcare costs and the inability to rely on PSA testing alone, as this results in over diagnosis and overtreatment. However, a major challenge will be the widespread clinical implementation of the new risk score, as deliberately avoiding diagnosis and subsequent treatment of low-grade tumours is currently subject to discussion and might be a barrier to overcome for both the patient and clinician. Although the results are in favour of the SelectMDx strategy, more research to further validate the accuracy and reliability of the biomarker-based risk score is needed, before the next challenging step in the direction of implementation in daily practice can be made.
In conclusion, implementation of the SelectMDx test, in the patient population with PSA levels >3 ng/mL to select patients for TRUS-guided biopsy, has the potential to improve the QoL of patients, while saving costs compared to the current SOC. This biomarker-based risk score can reduce over diagnosis and overtreatment with a slight chance of missing high-grade prostate cancer. In our present assessment, the expected loss in QALYs due to the latter was outweighed by the expected health gain, which was mainly caused by reducing the number of low-grade prostate cancer diagnoses and to a lesser extent by the reduction in prostate biopsies.
